New Pill Treatment for Cholesterol Management
Recent developments in medication suggest that a new daily pill might offer a simpler approach to managing cholesterol levels and potentially lowering the likelihood of heart attacks and strokes.
The drug, Obicetrapib, is currently being tested in a Phase 3 clinical trial at Monash University in Australia.
This trial included over 2,500 participants, averaging around 65 years old, all of whom had either a diagnosis of heart disease or naturally high cholesterol levels.
Every participant was given what researchers deemed the “maximum tolerance” of existing cholesterol-lowering therapies. Some were administered Obicetrapib while others received a placebo, continuing their regular cholesterol medications.
After a duration of 12 weeks, those taking Obicetrapib experienced a reduction in LDL cholesterol by about 32.6%, along with a 33.5% decrease in lipoprotein (A) [Lp(a)], as reported in a university press release.
The results were shared at the UK’s European Atherosclerosis Association Conference and featured in the esteemed New England Journal of Medicine.
Stephen Nichols, director of Monash University’s Victorian Heart Institute, pointed out that many high-risk individuals often don’t have access to the best available treatments for effectively lowering their cholesterol.
“Many at high risk for heart attacks and strokes know that current treatments fall short in managing their cholesterol,” Nichols stated.
“Obicetrapib presents a promising alternative. Not only did it lower LDL cholesterol significantly, but we also noted a decline in LP(a) levels,” he added.
Low-density lipoproteins (LDLs), typically referred to as “bad cholesterol,” can contribute to serious health issues when levels are elevated. They can build up in blood vessels, heightening the risk of heart-related events.
Lipoprotein (A) or LP (A), notably, is a genetic risk factor that can raise the likelihood of heart attacks, and unfortunately, it can’t be changed through lifestyle or medication.
Researchers indicated that Obicetrapib was well tolerated among participants, which is good news. “This could be a significant asset in the fight against heart disease,” Nichols concluded. “It seems convenient and effective and might address gaps in treatment for those with limited options.”
The study received backing from Newamsterdam Pharma, the drug’s developer, yet there are some caveats acknowledged by the researchers.
Notably, participants weren’t selected based on elevated LP (A) levels, meaning it remains unclear how effective the medication is for those with higher protein levels. Additionally, while LDL changes were examined, the actual impact on heart attack or stroke occurrences wasn’t measured.
The researchers pointed out that more extensive studies are needed, involving longer follow-ups and a more diverse group of patients.
Further comments from the researchers are awaited.
